COVID-19 in a lung transplant recipient: Exploring the diagnostic role of circulating exosomes and the clinical impact of advanced immunosuppression

Transpl Infect Dis. 2021 Apr;23(2):e13480. doi: 10.1111/tid.13480. Epub 2020 Oct 13.

Abstract

Exosomes isolated from plasma of lung transplant recipients with allograft injury contain donor-derived lung self-antigens (collagen V and Kα1 tubulin) and human leukocyte antigen (HLA) molecules. We present a case of a 76-year-old, female lung transplant recipient treated for acute cellular rejection with methylprednisolone and anti-thymocyte globulin, who subsequently contracted SARS-CoV-2 and developed a sharp increase in the mean fluorescent intensity of anti-HLA antibodies. Analysis of circulating exosomes during rejection, but before SARS-CoV-2 infection, revealed the presence of lung self-antigens and HLA class II molecules. After the patient contracted SARS-CoV-2, exosomes with the SARS-CoV-2 spike protein were also found. After resolution of infectious symptoms, exosomes with SARS-CoV-2 spike protein were no longer detected; however, exosomes with lung self-antigens and HLA class II molecules persisted, which coincided with a progressive decline in spirometric flows, suggesting chronic lung allograft dysfunction. We propose that the analysis of circulating exosomes may be used to detect allograft injury mediated by both rejection and infection. Furthermore, the detection of exosomes containing viral proteins may be helpful in identifying allograft injury driven by viral pathogens.

Keywords: COVID-19; allograft dysfunction; exosomes; lung self antigens; lung transplant; rejection.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antilymphocyte Serum / therapeutic use
  • Autoantigens / immunology
  • Autoantigens / metabolism
  • Bronchiolitis Obliterans
  • COVID-19 / immunology
  • COVID-19 / metabolism*
  • Collagen Type V / immunology
  • Collagen Type V / metabolism
  • Disease Progression
  • Exosomes / metabolism*
  • Female
  • Glucocorticoids / adverse effects
  • Glucocorticoids / therapeutic use
  • Graft Rejection / drug therapy*
  • HLA Antigens / immunology
  • HLA Antigens / metabolism
  • Histocompatibility Antigens Class II / immunology
  • Histocompatibility Antigens Class II / metabolism*
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Lung Transplantation*
  • Methylprednisolone / adverse effects
  • Methylprednisolone / therapeutic use
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / metabolism
  • Spike Glycoprotein, Coronavirus / immunology
  • Spike Glycoprotein, Coronavirus / metabolism*
  • Tubulin / immunology
  • Tubulin / metabolism

Substances

  • Antilymphocyte Serum
  • Autoantigens
  • Collagen Type V
  • Glucocorticoids
  • HLA Antigens
  • Histocompatibility Antigens Class II
  • Immunosuppressive Agents
  • Spike Glycoprotein, Coronavirus
  • Tubulin
  • spike protein, SARS-CoV-2
  • Methylprednisolone